---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-003545"
form_type: "8-K"
ticker: null
cik: "0001831874"
company_name: "Iris Acquisition Corp"
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:18:56.774191+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Iris Acquisition Corp restates Q2 and Q3 2024 financials over undisclosed related party loan

## Summary
- Determined unaudited financials for June 30, 2024 and Sept 30, 2024 should no longer be relied upon.
- A $1.216M loan from Hana Immunotherapeutics (affiliate of Liminatus Pharma CEO) to fund sponsor managing member acquisition was omitted.
- Loan was a material related party transaction that required disclosure; Audit Committee discussed with auditor Marcum LLP.
- Loan settled on Dec 29, 2024 via delivery of shares in a private Korean company.
- Former managing member Columbass resigned Oct 30, 2024; Iris Equity Holdings appointed as managing member.

## SEC filing metadata
- accession: 0001104659-25-003545
- form_type: 8-K
- cik: 0001831874
- company_name: Iris Acquisition Corp
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 4.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/0001104659-25-003545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/tm253036d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-003545
- JSON: https://secwatch.observer/filing/0001104659-25-003545.json
- Plain text: https://secwatch.observer/filing/0001104659-25-003545.txt

## Key facts
- Auditor Changes
  Iris Acquisition Corp reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: Marcum LLP
  source text: determined that the unaudited financial statements for the quarters ended June 30, 2024 and September 30, 2024 should no longer be relied upon.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/0001104659-25-003545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.